Skip to main content

Vasculitis

GCA temporal artery

Giant Cell Arteritis Novel Treatment Options

Giant cell arteritis is associated with significant treatment related morbidity due to the dependence on glucocorticoids as a treatment option. After sixty years of therapeutic stagnation, these are exciting times in the management of GCA. At this year's ACR Convergence meeting, encouraging data

Read Article
ICYMI: COVID-19 in Patients with Primary Systemic Vasculitis and Polymyalgia Rheumatica Dr. Bella Mehta ( @bella_mehta) interviews Dr. Sebastian Sattui about abstract #0952 presented at the #ACR21 annual meeting.https://t.co/UN66qOGqRd

Dr. John Cush @RheumNow( View Tweet )

Nov 27, 2021
FDA Session Review: Dr. Arthur Kavanaugh discussed the FDA session presented at the ACR21meeting, including safety data and new approvals and indications in several rheumatic diseases, including lupus, ANCA-associated vasculitis, lupus nephritis and more.https://t.co/5YkbzDv0YR https://t.co/MS9KNIfm2m
Dr. John Cush @RheumNow( View Tweet )
Nov 24, 2021
COVID-19 in Patients with Primary Systemic Vasculitis and Polymyalgia Rheumatica Dr. Bella Mehta ( @bella_mehta) interviews Dr. Sebastian Sattui about abstract #0952 presented at the #ACR21 annual meeting.https://t.co/BYyz0Xj1Fj

Dr. John Cush @RheumNow( View Tweet )

Nov 24, 2021
Giant-Cell_Vasculitis.jpg

Top vasculitis takeaways from ACR 2021

There were several hot topics at ACR21. Here I concentrate on top abstracts in vasculitis. 

Read Article
In case you missed it… Watch: What's Cool and Hot in Vasculitis with Dr. Janet Pope (@Janetbirdope ) #ACR21https://t.co/JbhQWeejy7 https://t.co/qlCCk3MXKu
Dr. John Cush @RheumNow( View Tweet )
Nov 13, 2021
audience learn

Day 4 Report from ACR21

Nov 10, 2021

My favorite three presentations from day 4 (Tuesday) at ACR 2021 included the following.

Read Article
📢No difference in ESRD or mortality with RTX-based vs CYC-based induction regimen in ANCA #Vasculitis #ACR21 https://t.co/Bdz5t2uyHi
Guy Katz, MD @GuyKatzMD( View Tweet )
Nov 09, 2021
#ACR21 #ACR2021 Clinical Pearls 🚨 Thread Alert 1/n 💥AAV does not typically cause hard palate lesions➡️consider: Cocaine induced midline destructive lesion(HNE+)/Malignancy 💥Limited GPA can be ANCA negetive in 50% 💥 oral cavity examination is a must in Rheum https://t.co/RxkLiGdcJt
EnvisionRheumat @ERheumat( View Tweet )
Nov 09, 2021
#ACR21 TM24. Hydralazine-induced ANCA vasculitis presenting with chondritis. Labs: +ANA +Anti-histone +p-ANCA, +MPO and +PR3 @Rheumnow https://t.co/YQvqj0vCHp https://t.co/LPyVYYzLtI
Nov 09, 2021
#ACR21 2022 ACR/EULAR GPA Criteria ▶️Classification, NOT diagnostic! ⭐️Clinical, lab, imaging, and biopsy criteria ⭐️+5 pts for cANCA or PR3, negative pts for pANCA or MPO, or eosinophilia @RheumNow https://t.co/6YWmabNzuH https://t.co/vg8zaFt5dR
Nov 09, 2021
ACR/EULAR Classification Criteria for ANCA vasculitis, updated from prior Similar disclaimer; these are for use AFTER the diagnosis of small or medium vasculitis has been made Great international effort, kudos to all involved #ACR21 #ACRambassador https://t.co/a29TVvzVF7
Mike Putman @EBRheum( View Tweet )
Nov 09, 2021
#ACR21 new 2022 classification criteria by ACR/EULAR for AAV 💥GPA-Sensitivity-92%, Specificity-94% 💥MPA-Sensitivity-91%, Specificity-94% 💥EGPA-Sensitivity-85%, Specificity-99% 💥Score based https://t.co/61SOl4Tovg
EnvisionRheumat @ERheumat( View Tweet )
Nov 09, 2021
What's Cool and Hot in Vasculitis: Dr. Janet Pope reviews abstracts #0505, #0466, #0430, #0507 and #0504, being presented at the #ACR21 annual meeting.https://t.co/7XwjFuJEMM https://t.co/BC9wjPzNC0
Dr. John Cush @RheumNow( View Tweet )
Nov 09, 2021
#ACR21 2022 ACR/EULAR MPA Criteria ▶️Classification, NOT diagnostic! ⭐️Clinical: negative for nasal GPA symptoms ⭐️Lab: +6 for pANCA or MPO, negative for cANCA/PR3 or eosinophilia @RheumNow https://t.co/6YWmabNzuH https://t.co/XVzBF2KONp
Nov 09, 2021
#ACR21 2022 ACR/EULAR Large Vessel Vasculitis Criteria: 🌎One reason for updating 31 year old criteria -> now an international effort that better reflects heterogeneous global disease @RheumNow https://t.co/6YWmabNzuH https://t.co/YXm85uQZCK
Nov 09, 2021
ACR/EULAR Classification Criteria for Large Vessel Vasculitis (TAK/GCA), updated from prior to include imaging Must emphasize typical disclaimers; these are for classification, not specifically for diagnosis Great effort and useful result, esp for trials #ACR21 @petercgrayson https://t.co/IYFyh5oYBT
Mike Putman @EBRheum( View Tweet )
Nov 09, 2021
#ACR21 2022 ACR/EULAR GCA Criteria ▶️Classification, NOT diagnostic! ⭐️Must be >50yo ⭐️Clinical, lab, imaging, and biopsy findings +TA biopsy or Halo sign = 5 points, 6+ points needed for classification @RheumNow https://t.co/6YWmabNzuH https://t.co/cZVrWA02U6
Nov 09, 2021
#ACR21 #AbstrL21 Phase III RCT which stratified pts using FFS showed no superiority of Rituximab vs SOC for remission induction of EGPA #vasculitis at Day 180 (63.5% vs 60.4%). No difference in secondary endpoints, safety or subgroup analyses @RheumNow https://t.co/AbdAvlU0Bg https://t.co/yta1CM7hrs
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Nov 09, 2021
IL17 IS Impt in giant cell arthritis. Who would’ve thought that #secukinumab would treat #GCA? More options for pts. Only 52 pts but maybe another Rx for GCA? #ACR21 abst#L19 https://t.co/dwbPmGswQ9
Nov 09, 2021
#ACR21 L19: TitAIN: Secukinumab for GCA ⭐️Phase 2 study with n=52 ⭐️70% of SEC sustained remission at wk 28 vs 20% PBO, 59% at week 52 vs 8% ⬇️Cumulative prednisolone through wk 52 (2.8g v 3.4g) - Looking forward to larger study @Rheumnowhttps://t.co/cuM9LcEr4u https://t.co/TmyS0kixFg
Nov 09, 2021
IL-17i for GCA? TitAIN study met all endpoints! phase II: 52 pt DBRPCT 1:1 for 52 weeks secukinumab vs PCB 👉effective sustained remission 👉longer time to GCA flare 👉lower dose of steroids by week 52 👉no increase in AEs #ACR21 @rheumnow Abst#L19 https://t.co/Xi3Iz6Em0R
TheDaoIndex @KDAO2011( View Tweet )
Nov 09, 2021
Secukinumab in GCA, phase 2 (TitAIN): I can't deny this is promising, but phase 2 needs to be interesting both arms did worse than equivalents in GiACTA, TCZ phase 2 (?looser flare def) @drpnash: "Bring on the phase 3 trials" (recruitment started👀) #ACR21 ABSTL19 @RheumNow https://t.co/25OAL9BqIZ
Nov 09, 2021
ARIAA Study - Abatacept Reverses ACPA+ Subclinical Arthritis: Dr. Jack Cush discusses abstract #0455, a preclinical RA intervention trial - abatacept or placebo given to at risk individuals (arthralgias, CCP+, MRI+) for 6 months, presented at #ACR21.https://t.co/fz1hPTleMn https://t.co/V4PsPZ0ZwF
Dr. John Cush @RheumNow( View Tweet )
Nov 09, 2021
Impressive case of vasculitis – should be part of @ACRheum image bank #ThievesMarket #ACR21 Abst#TM20 @rheumnow https://t.co/YiBikROuzb
TheDaoIndex @KDAO2011( View Tweet )
Nov 09, 2021
×